19 November 2019 - Medexus Pharmaceuticals today announced that Health Canada has granted priority review status for the new drug submission for Gliolan (5-aminolevulinic acid hydrochloride). 

 Gliolan is used for guiding maximal surgical resection of high-grade gliomas (malignant brain tumours) in adults. Gliolan assists neurosurgeons to better visualise and more completely remove gliomas by causing them to become fluorescent and glow during surgery. 

Medexus anticipates filing the submission in 2019 for approval to market and sell Gliolan in Canada.

Priority review status assigns eligible submissions a shortened review target of 180 days, in comparison to 300 days for non-priority review.

Read Medexus Pharmaceuticals press release